These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31584850)

  • 21. Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy.
    Bellone M; Bregni M; Bronte V; Ugel S; Ferrucci PF; Di Nicola M; Nisticò P; Zuccolotto G; Rosato A; Russo V; Sica A; Colombo MP
    Cancer Immunol Immunother; 2022 Jul; 71(7):1777-1786. PubMed ID: 34755203
    [No Abstract]   [Full Text] [Related]  

  • 22. The right patient for the right therapy: 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 11-13, 2015.
    Miller M; Jahndel V; Kutscher S; Mahr A; Rae R; Kloke BP
    Cancer Immunol Immunother; 2016 Oct; 65(10):1277-87. PubMed ID: 27259506
    [No Abstract]   [Full Text] [Related]  

  • 23. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
    Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
    J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer Neoantigens and Applications for Immunotherapy.
    Desrichard A; Snyder A; Chan TA
    Clin Cancer Res; 2016 Feb; 22(4):807-12. PubMed ID: 26515495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Checkpoint inhibitors for cancer immunotherapy. Multiple checkpoints on the long road towards cancer immunotherapy.
    Phan TG; Long GV; Scolyer RA
    Immunol Cell Biol; 2015 Apr; 93(4):323-5. PubMed ID: 25686808
    [No Abstract]   [Full Text] [Related]  

  • 26. Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy.
    Musetti S; Huang L
    ACS Nano; 2018 Dec; 12(12):11740-11755. PubMed ID: 30508378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant.
    Overwijk WW
    Curr Opin Immunol; 2017 Aug; 47():103-109. PubMed ID: 28806603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
    Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
    Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next generation approaches for tumor vaccination.
    Patel A; Kaufman HL; Disis ML
    Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy.
    Zhao P; Xu Y; Ji W; Li L; Qiu L; Zhou S; Qian Z; Zhang H
    Int J Nanomedicine; 2022; 17():73-89. PubMed ID: 35027827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In situ antitumor vaccination: Targeting the tumor microenvironment.
    Li H; Yu J; Wu Y; Shao B; Wei X
    J Cell Physiol; 2020 Jul; 235(7-8):5490-5500. PubMed ID: 32030759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.
    Mougel A; Terme M; Tanchot C
    Front Immunol; 2019; 10():467. PubMed ID: 30923527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference.
    Hubbard-Lucey VM; Tontonoz MJ
    Cancer Immunol Res; 2016 Jan; 4(1):3-11. PubMed ID: 27119139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
    Collins JM; Redman JM; Gulley JL
    Expert Rev Vaccines; 2018 Aug; 17(8):697-705. PubMed ID: 30058393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12.
    Bozeman EN; He S; Shafizadeh Y; Selvaraj P
    Hum Vaccin Immunother; 2016; 12(2):421-30. PubMed ID: 26308597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for the treatment of breast cancer.
    Ernst B; Anderson KS
    Curr Oncol Rep; 2015 Feb; 17(2):5. PubMed ID: 25677118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recruitment of dendritic cells using 'find-me' signaling microparticles for personalized cancer immunotherapy.
    Lee JA; Shin JM; Song SH; Kim CH; Son S; Shin S; Park JH
    Biomaterials; 2022 Mar; 282():121412. PubMed ID: 35184011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward integrative cancer immunotherapy: targeting the tumor microenvironment.
    Emens LA; Silverstein SC; Khleif S; Marincola FM; Galon J
    J Transl Med; 2012 Apr; 10():70. PubMed ID: 22490302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach.
    Kim CG; Sang YB; Lee JH; Chon HJ
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.